- American City Business Journals•21 minutes ago
Biogen has reached a $1.25 billion settlement and licensing agreement with Danish biotech Forward Pharma to resolve a dispute over a patent on the Cambridge company’s top-selling multiple sclerosis drug. The deal, which gives Biogen (BIIB) a license to Forward Pharma’s intellectual property, could help the Cambridge company extend the life of Tecfidera, which accounts for around a third of its total revenues. Forward Pharma (FWP) had claimed that Biogen infringed on its patent regarding the dosage of the drug’s key ingredient.
- MarketWatch•2 hours ago
Biogen Inc. said Tuesday morning that it had agreed to pay $1.25 billion in cash to license all of Forward Pharma's intellectual property, sending Forward Pharma shares skyrocketing 52.6% in pre-market ...
- Business Wire•2 hours ago
Biogen Inc. today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma’s shareholders and other customary conditions.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||282.82 x 100|
|Ask||286.23 x 300|
|Day's Range||281.08 - 284.55|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.95|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|